Quick answers
- What is Conjugated estrogens/bazedoxifene used for?
- The FDA-approved label (Duavee, U.S. Pharmaceuticals, July 31, 2026) says: “DUAVEE is indicated in women with a uterus for: DUAVEE is a combination of conjugated estrogens with an estrogen agonist/antagonist indicated for treatment of the following conditions in women with a uterus: • Treatment of moderate to severe vasomotor symptoms associated with menopause • Prevention of postmenopausal osteoporosis Limitation of Use …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Conjugated estrogens/bazedoxifene have a boxed warning?
- Yes. The FDA label for Duavee has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Conjugated estrogens/bazedoxifene?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Conjugated estrogens/bazedoxifene been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Conjugated estrogens/bazedoxifene?
- 2 companies list prescription products of Conjugated estrogens/bazedoxifene in the FDA NDC Directory, including U.S. Pharmaceuticals and Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc..
What Conjugated estrogens/bazedoxifene is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
DUAVEE is indicated in women with a uterus for: DUAVEE is a combination of conjugated estrogens with an estrogen agonist/antagonist indicated for treatment of the following conditions in women with a uterus: • Treatment of moderate to severe vasomotor symptoms associated with menopause • Prevention of postmenopausal osteoporosis Limitation of Use …
— FDA label: Duavee, U.S. Pharmaceuticals, effective July 31, 2026. Read the full label on DailyMed →
The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
2 of 2 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Duavee |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| bazedoxifene acetate 20 mg · estrogens, conjugated 0.45 mg tablet, film coated | Brand: Duavee | $6.48 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA022247 DUAVEE | Wyeth Pharms | October 3, 2013 | 6, latest March 4, 2024 2024: Labeling · 2022: Labeling · 2019: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1441392, 1441740 |
|---|---|
| SPL set ID of the quoted label | e16705d8-4472-4f83-96ac-69fa2be066cb |
| FDA labels (SPL) | 2 |
| FDA applications | NDA022247 |
| Active ingredients (FDA) | BAZEDOXIFENE ACETATE / ESTROGENS, CONJUGATED |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Duavee, U.S. Pharmaceuticals, effective July 31, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →